Harrow Health Reports Strong Q2 2025 Financial Results

The latest update is out from Harrow Health ( (HROW) ).

Harrow announced its second-quarter 2025 financial results, reporting a 30% increase in total revenues to $63.7 million compared to the previous year. The company highlighted significant growth in its VEVYE® and IHEEZO® products, with VEVYE® gaining nearly 3% in market share and 66% sequential prescription growth. Harrow also secured exclusive U.S. commercial rights to Samsung Bioepis’s ophthalmology biosimilar portfolio and acquired rights for BYQLOVI™, a new ophthalmic steroid. The strategic alliance with Apollo Care is expected to enhance patient access and insurance coverage, further driving growth. These developments position Harrow to exceed $280 million in revenue for 2025 and strengthen its market presence.

The most recent analyst rating on (HROW) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.

Spark’s Take on HROW Stock

According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.

Harrow Health’s strong revenue growth and positive technical indicators are offset by profitability challenges and high leverage. The earnings call provided a positive outlook, but valuation remains a concern due to negative earnings.

To see Spark’s full report on HROW stock, click here.

More about Harrow Health

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.

Average Trading Volume: 433,554

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.26B

For an in-depth examination of HROW stock, go to TipRanks’ Overview page.